{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Halozyme Therapeutics, Inc.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of October 31, 2025, Halozyme Therapeutics, Inc. shows a mildly bullish trend with mixed indicators, including a bullish monthly MACD and mildly bearish weekly MACD, while the overall sentiment is cautious due to some selling pressure.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of October 31, 2025, Halozyme Therapeutics, Inc. shows a mildly bullish trend with mixed signals across indicators, having underperformed the S&P 500 recently but delivering strong year-to-date and one-year returns.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of October 31, 2025, Halozyme Therapeutics, Inc. shows a mildly bullish technical trend, supported by a bullish monthly MACD and KST, despite some mixed signals from the weekly MACD and OBV indicating potential selling pressure.
Is Halozyme Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Halozyme Therapeutics, Inc. is fairly valued with a P/E ratio of 14, strong growth potential indicated by a PEG ratio of 0.22, and a remarkable ROE of 100.64%, outperforming peers and the S&P 500 over the past year.
Halozyme Therapeutics, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics
Halozyme Therapeutics, Inc. has recently adjusted its valuation, with its stock price at $67.03. Over the past year, it has achieved a 28.21% return, surpassing the S&P 500. The company exhibits strong financial metrics, including a P/E ratio of 14 and a remarkable return on equity of 100.64%.
Is Halozyme Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Halozyme Therapeutics, Inc. is fairly valued with a P/E ratio of 14, strong growth potential indicated by a PEG ratio of 0.22, and impressive returns of 28.21% over the past year, outperforming the S&P 500.
Is Halozyme Therapeutics, Inc. overvalued or undervalued?
As of October 17, 2025, Halozyme Therapeutics, Inc. is fairly valued with a P/E ratio of 14, strong growth potential indicated by a low PEG ratio of 0.22, and impressive returns of 28.21% over the past year, outperforming the S&P 500.
Halozyme Therapeutics Experiences Evaluation Revision Amidst Mixed Market Signals
Halozyme Therapeutics, Inc. has recently revised its market evaluation, with its stock priced at $66.97. The company has shown varied performance compared to the S&P 500, achieving a 13.16% return over the past year and a notable 152.72% return over five years, despite trailing the index's longer-term growth.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Halozyme Therapeutics, Inc. has a mildly bullish technical trend, supported by positive MACD and moving averages, despite recent underperformance against the S&P 500 and some bearish signals from Dow Theory.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Halozyme Therapeutics, Inc. has a mildly bullish technical trend, supported by positive MACD and moving averages, despite recent short-term underperformance compared to the S&P 500.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Halozyme Therapeutics, Inc. has a mildly bullish technical trend, supported by bullish MACD and Bollinger Bands, despite underperforming the S&P 500 recently while outperforming it year-to-date.
Halozyme Therapeutics Hits New 52-Week High of $79.46, Up 51.62%
Halozyme Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company boasts a market capitalization of USD 8,872 million, impressive management efficiency, and consistent positive financial results over six quarters, reinforcing its market position.
Halozyme Therapeutics Hits New 52-Week High of $79.31, Up 53% Yearly
Halozyme Therapeutics, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 8,872 million, the company has demonstrated impressive management efficiency and financial health, marked by significant growth in net profit and operating profits.
Halozyme Therapeutics Hits New 52-Week High of $77.95, Surges 52%
Halozyme Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has shown impressive growth over the past year, with significant increases in stock value, operational efficiency, and net profit, alongside effective debt management.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of August 6, 2025, Halozyme Therapeutics, Inc. shows a bullish trend supported by positive MACD and KST indicators, despite a bearish weekly RSI, while outperforming the S&P 500 in the short term but lagging over the past decade.
Is Halozyme Therapeutics, Inc. overvalued or undervalued?
As of July 7, 2025, Halozyme Therapeutics, Inc. is fairly valued with a P/E ratio of 14, an EV to EBITDA of 10.96, and a PEG ratio of 0.22, outperforming peers like Illumina and BioMarin, and achieving a year-to-date return of 60.38% compared to the S&P 500's 12.22%.
Halozyme Therapeutics, Inc. Reports Strong Financial Performance in Q2 2025
Halozyme Therapeutics, Inc. reported strong financial results for the quarter ending June 2025, showcasing significant growth in operating cash flow, net sales, and operating profit. The company also improved cost efficiency by reducing raw material costs, indicating robust operational performance and a solid market presence.
Is Halozyme Therapeutics, Inc. overvalued or undervalued?
As of May 13, 2025, Halozyme Therapeutics, Inc. is fairly valued with a P/E ratio of 14 and strong growth potential indicated by a low PEG ratio of 0.22, despite recent underperformance against the S&P 500, while showing a solid long-term growth outlook with a 106.09% return over the past five years.
Is Halozyme Therapeutics, Inc. technically bullish or bearish?
As of May 13, 2025, the trend is mildly bullish due to daily moving averages, but mixed signals from weekly bearish indicators suggest a cautious outlook.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
